3-(2-(DIMETHYLAMINO)ETHYL)-1H-INDOL-4-yl DERIVATIVES
Provided herein are compounds of Formula (I) (I), a compound selected from any of the compounds in Table 1, Table 2, Table 3, Table 4 or Table 5, or a pharmaceutically acceptable salt or deuterated form thereof, wherein R 1 , R 2 , R 1 and R 4 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of formula (I), or a compound selected from any of the compounds in Table 1, Table 2, Table 3, Table 4 or Table 5, or pharmaceutically acceptable salt or deuterated form thereof, and methods of using a compound of formula (I) or pharmaceutically acceptable salt or deuterated form thereof, e.g., in treating 5-HT 2 A receptor associated diseases or disorders.
1 . A compound selected from any one of the following structures, or a pharmaceutically acceptable salt or a deuterated form thereof:
2 . The compound of claim 1 , having the following structure:
or a pharmaceutically acceptable salt or deuterated form thereof.
3 . A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt or deuterated form thereof.
4 . A method of treating 5-HT 2 A receptor associated disease or disorder, comprising administering a compound of claim 1 , or a pharmaceutically acceptable salt or deuterated form thereof.
5 . The method of claim 4 , wherein the 5-HT 2 A receptor associated disease or disorder is an anxiety disorder, attention deficit hyperactivity disorder (ADHD), depression, cluster headache, diminished drive, burn-out, bore-out, migraine, Parkinson's disease, schizophrenia, an eating disorder, psychotic disorder, schizophrenia, schizophreniform disorder, schizoaffective disorder, bipolar I disorder, bipolar II disorder, major depressive disorder, psychotic depression, delusional disorders, shared psychotic disorder, Shared paranoia disorder, brief psychotic disorder, paranoid personality disorder, schizoid personality disorder, schizotypal personality disorder, social anxiety disorder, substance-induced anxiety disorder, selective mutism, panic disorder, panic attacks, agoraphobia, posttraumatic stress disorder (PTSD), premenstrual dysphoric disorder (PMDD), and premenstrual syndrome (PMS).
6 . The method of claim 5 , wherein the 5-HT 2 A receptor associated disease or disorder is depression
7 . The method of claim 6 , wherein the depression is treatment resistant depression.
8 . The method of claim 5 , wherein the 5-HT 2 A receptor associated disease or disorder is an eating disorder.
9 . The method of claim 8 , wherein the eating disorder is anorexia nervosa.
10 . The method of claim 5 , wherein the 5-HT 2 A receptor associated disease or disorder is an anxiety disorder.
11 . The method of claim 5 , wherein the 5-HT 2 A receptor associated disease or disorder is bipolar I disorder.
12 . The method of claim 5 , wherein the 5-HT 2 A receptor associated disease or disorder is bipolar II disorder.
13 . The method of claim 5 , wherein the 5-HT 2 A receptor associated disease or disorder is major depressive disorder.
14 . The method of claim 5 , wherein the 5-HT 2 A receptor associated disease or disorder is posttraumatic stress disorder (PTSD).